CHORDC2P

Across TCGA pan-cancer cohorts, CHORDC2P RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of CHORDC2P’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where CHORDC2P RNA is repressed in tumor relative to normal tissue. In most cancer types CHORDC2P is over-expressed in tumor, although a few such as THCA and PAAD show the opposite, repressed pattern.

THCA, HNSC, and LUSC are the cancer types where CHORDC2P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CHORDC2P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	All	All	−0.034	<.001	4	view →
HNSC	Female	IV	+0.141	.001	3	view →
LUSC	All	All	+0.084	.018	3	view →
PAAD	Female	All	−0.125	.014	2	view →
LUAD	All	III,IV	+0.056	.033	2	view →
LIHC	Male	All	+0.024	.028	2	view →
STAD	Male	II,III,IV	+0.040	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

CHORDC2P–THCA

Open the THCA breakdown →